ABSTRACT Among the side effects commonly reported with the use of /3-blockers are symptoms related to the central nervous system (CNS). In this study we compared the effects of four /3-blockers with different ancillary properties (atenolol, metoprolol, propranolol, and pindolol) all /3-blockers depressed heart rate to equivalent degrees. These results provide strong evidence that CNS effects of /3-blockers are modulated by the ancillary properties (e.g., lipophilicity, intrinsic sympathomimetic activity) of the drugs.
THERAPY AND PREVENTION-f-BLOCKADE
Sexual dysfunction has been reported in 5% to 50% of patients using fl-blockers, depending on the agent used, the dose and duration of treatment, population under study, and the means of evaluation (i.e., specifically assessing sexual function vs recording spontaneous patient complaints).2`22 However, none of the studies conducted to date have included laboratory assessment by objective techniques, such as nocturnal penile tumescence. Although there are many case reports and retrospective studies, few placebo-controlled, comparative studies of CNS effects of different fl-blockers are available. The purpose of this article is to report on a double-blind, placebo-controlled study of the CNS effects associated with four fl-blockers with different ancillary properties, with the use of both subjective and objective measures.
Materials and methods
Study design. This was a placebo-controlled, Latin-square design, double-blind study with five treatment periods of 1 week each separated by 2 week drug-free washout periods. The following medications were administered: 100 mg atenolol at 8:00 A.M. and placebo at 7:00 P.M., 100 mg metoprolol at 8:00 A.M. and 100 mg at 7:00 P.M., 10 mg pindolol at 8:00 A.M. and 10 mg at 7:00 P.M., 80 mg propranolol at 8:00 A.M. and 80 mg at 7:00 P.M., and placebo both at 8:00 A.M. and at 7:00 P.M.
Atenolol is a hydrophilic PI-selective blocker, metoprolol is a lipophilic fl1-selective blocker, and propranolol is a lipophilic nonselective fl-blocker. Pindolol is a nonselective lipophilic ,fblocker that also possesses intrinsic sympathomimetic activity. The patients were instructed to take the medications for 7 days from prepackaged blind blister cards. Laboratory evaluations were performed at the end of the seventh day of administration of drug (14 tablets ingested), beginning 1 hr after the ingestion of the 7:00 P.M. dose. After each 7 day treatment period with the active medication or placebo in the fashion described above, the subjects entered a drug-free washout period for 14 days. Patient compliance was ascertained by pill count of the blister cards and was verified by the time of the ingestion of each dose that was entered in the daily logs that the patients kept. Patients had strict instructions to contact the study coordinator or, in his absence, an investigator with any questions or difficulties in taking the medication. According to these measures of compliance only one of 1050 tablets was missed, and no tablet was missed on a sleep study day.
Subjects. Thirty healthy men from 23 to 40 years old (mean ± SD, 29.4 ± 4.3) were enrolled in the study. All subjects were screened for one or more of the following exclusion criteria: any acute illness or chronic disease, acute or chronic alcoholism, psychiatric disorders, chronic use of any prescribed and unprescribed medications or drugs, sinus bradycardia (pulse 60 beats/min), heart block greater than first degree, cardiac failure, bronQhospastic disease, diabetes, ischemic heart disease, impaired renal function, a history of adverse reaction to f-blocking drugs, evidence of noncompliance, and failure to provide written informed consent. Subjects with significant abnormalities on laboratory tests (routine blood chemistry [14 tests], complete blood count, and urinalysis) or psychologic or sexual dysfunction that was discovered on interview with a psychologist were also excluded.
Dependent measures. Drug effects were evaluated by means of both objective and subjective measures as follows. Daily questionnaires for sleep, mood, and sexual activity were completed during each of the drug periods. More extensive questionnaires pertaining to sexual activity, sleep, and mood were administered at the end of each treatment period before the objective testing in the laboratory. Measures of mood included standardized instruments such as the Depression Adjective Check List (DACL),23 the Profile of Mood States (PoMS),24 and the Spielberger Anxiety Inventory (STAI).25 In addition, the Tyrer self-rating scales26 were obtained both at the laboratory visit and in an abbreviated version on the daily questionnaires. Tests of auditory reaction time and visual reaction time and a coding vigilance test27 were also administered during the laboratory visit. An evaluation of subjective side effects (e.g., faintness, blacking out, blurred vision, hallucinations, nausea, constipation, cold hands and feet, flushing, dry mouth, and feeling better) was also included.
Multistage exercise stress testing on a bicycle was performed at around 9:00 P.M. approximately 2 hr after the ingestion of the evening dose of the study medication as follows: 50 W for 3 min, 75 W for 3 min, 100 W for 3 min, 125 W for 3 min, and 150 W for 3 min. The bicycle was calibrated by means of kilogram weights. Heart rate and systolic and diastolic blood pressure were measured in subjects at supine rest, sitting, at each exercise level, and immediately on completion of the exercise test. The suppression of exercise heart rate (heart rate during exercise at 125 W) compared with that after placebo was used as an indirect measure of efficacy of the f8-blockers.
Sleep laboratory (polysomnographic) evaluation. After administration of the questionnaire instruments, psychomotor assessment, and exercise testing, subjects were prepared for overnight sleep laboratory assessment. All sleep studies were conducted in a sound-proofed and electrically shielded chamber, and standardized sleep laboratory techniques were used for the recording and scoring of all sleep records. Specific measures included the following.
Electroencephalogram (EEG). Electrode sites for bilateral recording of the EEG were standard C4-C3, with A1-A2 reference sites. Gold-plated cup electrodes were secured by means of collodion, and signals were displayed on a Beckman type RM polygraph.
Electrooculogram. Recordings of eye movement were obtained by means of monopolar silver chloride electrodes placed over the outer canthi of the right and left eye and referenced to A2. Eye movements during REM sleep and phasic REM activity were scored according to the Pittsburgh method. 28 Electromyogram (EMG). Two silver chloride electrodes were attached to the subject's chin for continuous recording of the EMG. Reduction in electromyographic levels was used as an additional criterion for the onset of REM sleep.
Electrocardiogram. Recordings were obtained by placement of three self-adhesive electrodes on the precordium to obtain "modified lead V5." In addition, a cardiotachometer was used to convert electrocardiographic signals into heart rate.
Nocturnal penile tumescence (NPT). The NPT recording was obtained by means of a mercury-in-rubber strain gauge placed midway on the penile shaft. The tumescence gauge was connected to the polygraph, and was calibrated for millimeters of increase in penile circumference.
Subjective sleep reports. On awakening in the laboratory, all subjects were required to complete a brief sleep questionnaire. This included the Stanford Sleepiness Scale, subjective ratings of dream content and quality, and subjective reports of erection. The subjective disturbances of sleep were corroborated by objective polysomnographic measures obtained in the sleep laboratory. Total wakefulness after onset of sleep and total number of awakenings during the night were significantly higher in subjects on pindolol, propranolol, and metoprolol than in those on atenolol or placebo (table 2). These differences were highly statistically significant. Similar trends were seen on other measures of sleep continuity, time spent asleep, sleep latency, and sleep efficiency.
Although all lipophilic /3-blockers affected sleep continuity, only pindolol affected sleep architecture (table 2) . Specifically, a significant increase in REM sleep latency was observed (from 95.4 min on placebo to 175 min on pindolol). Probably as a result of the marked increase in REM latency, the total number of REM periods was decreased and total REM sleep time was significantly decreased by pindolol, but the latter was not affected by the other /-blockers. Once the first REM period began, REM sleep was not affected by pindolol. Thus, REM density and duration, REM activity, and REM density of the first, second, and third REM periods were not affected. Significant effects on CIRCULATION THERAPY AND PREVENTION-fl-BLOCKADE (table 4) . Although there were more days on which subjects reported erectile difficulties while on each of the drugs as compared with placebo, this difference was not significant. Efects on heart rate. As expected, /3-blockers, with exception of pindolol, depressed resting heart rate (table 5). Pindolol, probably as a result of its intrinsic sympathomimetic activity, caused a small but significant increase in resting heart rate. Similarly, the heart rate during sleep was depressed to the same degree by all /3-blockers, with the exception of pindolol, which caused an increase in heart rate (table 5). In contrast to these effects at rest, during exercise all /3-blockers, including pindolol, depressed the heart rate to equivalent degrees. Effects on blood pressure were similar to effects on heart rate. The effect of /3-blockers on heart rate remained constant throughout the night (p = .9383). Although atenolol was taken once a day and the other three /3-blockers were taken twice a day, atenolol did not have a lesser effect on heart rate even in the late sleep period (early morning hours) (table 5). DQ -daily questionnaire, which was filled out on each of the 5 days before sleep studies.
ASeven-point rating scale was used (1 to 7).
KOSTIS and ROSEN Previous studies have yielded conflicting results on the effect of /3-blockers on psychomotor performance.6 /3-Blockers have been found to be effective in control of stage fright,46 47 and improvement in performance of certain tasks, especially those tasks that are routine, repetitious, and do not require higher levels of intellectual activity, has been reported. In other instances, however, a decrement in performance has been noted in individuals perforning cognitive tasks that require more subtle or complex skills. Significant effects on visual reaction time, auditory reaction time, and a complex psychomotor test were not observed in this study. This could either imply that the tests used may not have been sensitive enough to detect effects on these measures, or that psychomotor performance in these subjects was not affected by the drugs and dosages used.
Although many patients that receive /3-blockers complain of sexual dysfunction, the exact mechanism of this phenomenon is not known. Up to 20% of men receiving fl-blockers for hypertension, especially when combined with diuretics, complain of erectile dysfunction or decreased libido. 20 21 In this study of healthy young men consistent effects on sexual activity, including those measured by the objective NPT test, were not observed. Although there was a trend toward fewer erections in subjects on the lipophilic drugs, this trend was not statistically significant, perhaps due to the brief duration of treatment periods.
Limitations of the study. Although the experimental design and procedures for data collection in our study were optimal, the findings of the study should be cautiously interpreted in view of certain limitations. The duration of treatment with each fl-blocker was limited to 7 days. While it is possible that atenolol would have produced similar effects if it had been administered for longer periods of time, this is not likely since significant differences in brain/plasma concentration ratios of lipophilic and hydrophilic fl-blockers have been shown to persist after long-term administration. 39 Another limitation of the present research is that we chose to study healthy men rather than the middle-aged patients with hypertension, arrhythmias, or angina to whom fl-blockers are usually administered. These patients are more likely to exhibit abnormalities in CNS function due to their age or cardiovascular disorder, and may respond differently to the drugs.
